Sökning: onr:"swepub:oai:gup.ub.gu.se/315125" > Phase III study of ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05742naa a2200997 4500 | |
001 | oai:gup.ub.gu.se/315125 | |
003 | SwePub | |
008 | 240910s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:148724527 | |
024 | 7 | a https://gup.ub.gu.se/publication/3151252 URI |
024 | 7 | a https://doi.org/10.1007/s11764-021-01160-12 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1487245272 URI |
040 | a (SwePub)gud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a van Leeuwen, Marieke4 aut |
245 | 1 0 | a Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire |
264 | c 2022-01-27 | |
264 | 1 | b Springer Science and Business Media LLC,c 2023 |
520 | a Purpose: The purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales. Methods: We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales. Results: Fifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items. Conclusions: The QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study. Implications for Cancer Survivors: The availability of this questionnaire will facilitate a standardized and robust assessment of the HRQOL of disease-free cancer survivors. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Omvårdnad0 (SwePub)303052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Nursing0 (SwePub)303052 hsv//eng |
653 | a Cancer survivor | |
653 | a Disease-free | |
653 | a Health-related quality of life | |
653 | a Oncology | |
653 | a Patient reported outcomes | |
653 | a Survivorship questionnaire | |
700 | 1 | a Kieffer, Jacobien M.4 aut |
700 | 1 | a Young, Teresa E.4 aut |
700 | 1 | a Annunziata, Maria Antonietta4 aut |
700 | 1 | a Arndt, Volker4 aut |
700 | 1 | a Arraras, Juan Ignacio4 aut |
700 | 1 | a Autran, Didier4 aut |
700 | 1 | a Hani, Hira Bani4 aut |
700 | 1 | a Chakrabarti, Manas4 aut |
700 | 1 | a Chinot, Olivier4 aut |
700 | 1 | a Cho, Juhee4 aut |
700 | 1 | a da Costa Vieira, Rene Aloisio4 aut |
700 | 1 | a Darlington, Anne Sophie4 aut |
700 | 1 | a Debruyne, Philip R.4 aut |
700 | 1 | a Dirven, Linda4 aut |
700 | 1 | a Doege, Daniela4 aut |
700 | 1 | a Eller, Yannick4 aut |
700 | 1 | a Eichler, Martin4 aut |
700 | 1 | a Friðriksdóttir, Nanna4 aut |
700 | 1 | a De Giorgi, Ugo4 aut |
700 | 1 | a Gioulbasanis, Ioannis4 aut |
700 | 1 | a Hammerlid, Eva,d 1957u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xhamev |
700 | 1 | a van Hemelrijck, Mieke4 aut |
700 | 1 | a Hermann, Silke4 aut |
700 | 1 | a Husson, Olga4 aut |
700 | 1 | a Jefford, Michael4 aut |
700 | 1 | a Johansen, Christoffer4 aut |
700 | 1 | a Johnson, Colin4 aut |
700 | 1 | a Kjaer, Trille Kristina4 aut |
700 | 1 | a Kontogianni, Meropi4 aut |
700 | 1 | a Lagergren, Pernilla4 aut |
700 | 1 | a Lidington, Emma4 aut |
700 | 1 | a Lisy, Karolina4 aut |
700 | 1 | a Morag, Ofir4 aut |
700 | 1 | a Nordin, Andy4 aut |
700 | 1 | a Al Omari, Amal S.H.4 aut |
700 | 1 | a Pace, Andrea4 aut |
700 | 1 | a De Padova, Silvia4 aut |
700 | 1 | a Petranoviæ, Duska4 aut |
700 | 1 | a Pinto, Monica4 aut |
700 | 1 | a Ramage, John4 aut |
700 | 1 | a Rammant, Elke4 aut |
700 | 1 | a Reijneveld, Jaap4 aut |
700 | 1 | a Serpentini, Samantha4 aut |
700 | 1 | a Sodergren, Sam4 aut |
700 | 1 | a Vassiliou, Vassilios4 aut |
700 | 1 | a Verdonck-de Leeuw, Irma4 aut |
700 | 1 | a Vistad, Ingvild4 aut |
700 | 1 | a Aaronson, Neil K.4 aut |
700 | 1 | a van de Poll-Franse, Lonneke V.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org |
773 | 0 | t Journal of Cancer Survivorshipd : Springer Science and Business Media LLCg 17:4, s. 1111-1130q 17:4<1111-1130x 1932-2259x 1932-2267 |
856 | 4 8 | u https://gup.ub.gu.se/publication/315125 |
856 | 4 8 | u https://doi.org/10.1007/s11764-021-01160-1 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:148724527 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy